SOPH — Sophia Genetics SA Income Statement
0.000.00%
- $202.50m
- $152.30m
- $65.17m
- 41
- 27
- 37
- 27
Annual income statement for Sophia Genetics SA, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 20-F | 20-F | 20-F | 20-F |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 28.4 | 40.5 | 47.6 | 62.4 | 65.2 |
Cost of Revenue | |||||
Gross Profit | 17.7 | 25.2 | 31.3 | 42.9 | 43.9 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 65.8 | 112 | 135 | 137 | 132 |
Operating Profit | -37.4 | -71.5 | -87.8 | -74.8 | -66.6 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -41.2 | -73.5 | -87.6 | -78.5 | -61.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -39.3 | -73.7 | -87.4 | -79 | -62.5 |
Net Income Before Extraordinary Items | |||||
Net Income | -39.3 | -73.7 | -87.4 | -79 | -62.5 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -39.3 | -73.7 | -87.4 | -79 | -62.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.621 | -1.33 | -1.36 | -1.22 | -0.946 |
Dividends per Share |